San Diego, California, USA, November 17, 2026
Inhibrx Biosciences, Inc. has announced encouraging updated clinical data for ozekibart (INBRX-109), an investigational biologic therapy being evaluated in combination with irinotecan and temozolomide for patients with relapsed or refractory Ewing sarcoma. The results come from the Phase 1/2 expansion study and are scheduled for presentation at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting. The combination demonstrated an overall response rate of 62.7% and a disease control rate of 86.3% among response-evaluable patients, with evidence of durable responses in this difficult-to-treat cancer population. The findings highlight the potential of combining a targeted investigational antibody with established chemotherapy agents to address an important unmet medical need.
Ozekibart Combination Demonstrates Encouraging Tumour Response
According to Inhibrx, the study evaluated ozekibart alongside irinotecan and temozolomide (IRI/TMZ) in adolescents and adults with relapsed or refractory Ewing sarcoma. At the September 18, 2026 data cutoff, 60 patients, including nine adolescents, had been enrolled and treated, with 22 patients continuing on active treatment. Among the 51 patients whose responses could be evaluated, the combination achieved an overall response rate (ORR) of 62.7%, consisting of two complete responses and 30 partial responses. In addition, 43 of the 51 patients, representing 84.3%, experienced measurable reductions in tumour size from baseline. Twelve further patients achieved stable disease, contributing to a disease control rate (DCR) of 86.3%. These results indicate that a substantial proportion of evaluable patients experienced tumour shrinkage or disease stabilisation during treatment. However, the findings are from an early-phase clinical study and require confirmation through further clinical development.
Durable Responses and Progression-Free Survival Findings
The updated analysis also reported a median progression-free survival (mPFS) of 6.0 months, with a 95% confidence interval of 4.6 to 7.4 months. Durable clinical benefit lasting more than six months was observed in 18 patients, including one complete response, one case of stable disease and 16 partial responses. Notably, one patient maintained an ongoing partial response for more than two years. At the data cutoff, 14 response-evaluable patients remained progression-free, including two patients whose progression-free survival exceeded 12 months. Inhibrx compared the combination results with historical outcomes for irinotecan and temozolomide alone in relapsed or refractory Ewing sarcoma, which typically produce an ORR of approximately 15% to 30% and a median progression-free survival of around three to four months. Although this comparison suggests a potentially meaningful improvement, it is based on historical benchmarks rather than a direct head-to-head clinical trial. Further studies will be important to establish the treatment’s efficacy and durability.
Safety Profile and Ozekibart’s Clinical Development
Inhibrx reported that the combination continued to demonstrate an acceptable and manageable safety profile, consistent with the known toxicities associated with irinotecan, temozolomide and DR5 agonism. The company also reported no evidence of unexpected cumulative hepatotoxicity. Ozekibart is an investigational, precision-engineered tetravalent death receptor 5 (DR5) agonist antibody designed to activate DR5 and promote tumour-biased cell death. Its engineering is intended to optimise receptor clustering and activation without requiring secondary crosslinking, an approach developed in response to severe liver toxicity observed with some first-generation DR5-targeting agents. The investigational therapy has also advanced in another cancer indication: the U.S. Food and Drug Administration (FDA) has accepted Inhibrx’s biologics license application (BLA) for ozekibart in conventional chondrosarcoma. This regulatory filing concerns a separate indication and does not represent approval for Ewing sarcoma. The company plans to discuss the Ewing sarcoma findings with the FDA and intends to advance its development plans with the goal of making the treatment available to patients as soon as possible, subject to further clinical and regulatory requirements. The updated data will be presented by Varun Monga, M.D., during the CTOS 2026 Annual Meeting poster session on November 19, 2026.
The presentation is titled “Phase 1/2 Study of the Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) Combined with Irinotecan (I) and Temozolomide (T) in Adolescents and Adults with Ewing Sarcoma (EWS).” Ewing sarcoma is a rare and aggressive cancer that primarily affects bones and surrounding soft tissues, with limited treatment options for patients whose disease returns or does not respond to initial therapy. Inhibrx estimates that approximately 300 new cases are diagnosed annually in the United States, with around 2,500 people currently living with the disease. While the updated findings provide a positive clinical signal, ozekibart remains investigational for Ewing sarcoma, and additional evidence and regulatory review will be necessary before it can become an approved treatment option.
Source: Inhibrx Biosciences press release



